Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

RIPK2 influences bone metastasis in prostate cancer through macrophage-tumor cell interaction: a mechanistic study.

Created on 13 Nov 2026

Authors

Huaguo Zhao, Dan Wu, Rong Ren, Licheng Ni

Published in

Minerva urology and nephrology. Nov 13, 2026. Epub Nov 13, 2026.

Abstract

Bone metastasis is a leading cause of mortality in prostate cancer (PCa) patients with limited treatment options. Myeloid-tumor cell interactions in the tumor microenvironment (TME) critically drive metastasis, but the mechanisms involved are poorly understood. Elucidating the myeloid-tumor cell crosstalk is crucial for developing novel anti-metastatic therapies.
Myeloid and tumor cell subsets were identified through single-cell RNA sequencing and copy number variation (CNV) analysis. Key signaling axes between these subsets were identified through cell-cell communication analysis. Molecular biological experiments, including qRT-PCR, Western blot, and flow cytometry, were conducted to investigate the effects of RIPK2+ macrophages on malignant tumor cell phenotypes.
RIPK2+ macrophages and disseminated tumor cells (DTCs) were enriched in tumor samples. DTCs exhibited high CNV scores and metastatic potential. RIPK2+ macrophages displayed unique antigen-presenting and immunoregulatory characteristics and engaged in high-intensity interactions with DTCs via the THBS1-CD47 signaling axis. In vitro, RIPK2 upregulated THBS1 and CD47, promoted their protein interaction, and enhanced PCa cell proliferation, migration, and invasion while repressing apoptosis.
Revealed by single-cell sequencing and molecular biological experiments, RIPK2+ macrophages promote PCa bone metastasis through the THBS1-CD47 axis. The findings expand the understanding of myeloid-tumor cell interaction networks in the TME and provide a theoretical basis for developing TME-targeted therapeutic strategies.

PMID:
43021712
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 6
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement